SHapley Additive exPlanations (SHAP) highlighted age, tumor size, alpha-fetoprotein (AFP), and RT status as the dominant contributors.<h4>Conclusions</h4>In advanced HCC, adding RT to immune-targeted therapy was associated with improved response and survival. This evidence concerns the gene AFP and hepatocellular carcinoma.